| Year |
Citation |
Score |
| 2024 |
Chua V, Lopez-Anton M, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T, ... Aplin AE, et al. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Science Signaling. 17: eadn8376. PMID 38861613 DOI: 10.1126/scisignal.adn8376 |
0.434 |
|
| 2024 |
Cavallo MR, Yo JC, Gallant KC, Cunanan CJ, Amirfallah A, Daniali M, Sanders AB, Aplin AE, Pribitkin EA, Hartsough EJ. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma. Cell Death Discovery. 10: 175. PMID 38622136 DOI: 10.1038/s41420-024-01945-0 |
0.403 |
|
| 2024 |
Kadamb R, Anton ML, Purwin TJ, Chua V, Seeneevassen L, Teh J, Angela Nieto M, Sato T, Terai M, Roman SR, De Koning L, Zheng D, Aplin AE, Aguirre-Ghiso J. Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP signaling in dormant disseminated uveal melanoma. Biorxiv : the Preprint Server For Biology. PMID 38496663 DOI: 10.1101/2024.03.05.583565 |
0.307 |
|
| 2023 |
Baqai U, Kurimchak AM, Trachtenberg I, Purwin TJ, Haj JI, Han A, Luo K, Pachon NF, Jeon A, Chua V, Davies MA, Gutkind JS, Benovic JL, Duncan JS, Aplin AE. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma. The Journal of Biological Chemistry. 105418. PMID 37923138 DOI: 10.1016/j.jbc.2023.105418 |
0.485 |
|
| 2023 |
Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, ... ... Aplin AE, et al. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell Reports. Medicine. 101244. PMID 37858338 DOI: 10.1016/j.xcrm.2023.101244 |
0.4 |
|
| 2023 |
Rosenbaum SR, Caksa S, Stefanski CD, Trachtenberg IV, Wilson HP, Wilski NA, Ott CA, Purwin TJ, Haj JI, Pomante D, Kotas D, Chervoneva I, Capparelli C, Aplin AE. SOX10 loss sensitizes melanoma cells to cytokine-mediated inflammatory cell death. Molecular Cancer Research : McR. PMID 37847239 DOI: 10.1158/1541-7786.MCR-23-0290 |
0.392 |
|
| 2023 |
Purwin TJ, Caksa S, Sacan A, Capparelli C, Aplin AE. Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas. Iscience. 26: 107472. PMID 37636077 DOI: 10.1016/j.isci.2023.107472 |
0.39 |
|
| 2023 |
Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, Baqai U, Aumiller JL, Bechtel N, Hunter E, Danielson M, Terai M, Wedegaertner PB, Sato T, Landreville S, ... ... Aplin AE, et al. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth. Cancers. 15. PMID 37444561 DOI: 10.3390/cancers15133451 |
0.352 |
|
| 2023 |
Glasheen MQ, Caksa S, Young AG, Wilski NA, Ott CA, Chervoneva I, Flaherty KT, Herlyn M, Xu X, Aplin AE, Capparelli C. Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma. Molecular Cancer Therapeutics. PMID 37343247 DOI: 10.1158/1535-7163.MCT-23-0025 |
0.38 |
|
| 2023 |
Bhardwaj M, Lee JJ, Versace AM, Harper SL, Goldman AR, Crissey MAS, Jain V, Singh MP, Vernon M, Aplin AE, Lee S, Morita M, Winkler JD, Liu Q, Speicher DW, et al. Lysosomal lipid peroxidation regulates tumor immunity. The Journal of Clinical Investigation. PMID 36795483 DOI: 10.1172/JCI164596 |
0.317 |
|
| 2022 |
Lapadula D, Lam B, Terai M, Sugase T, Tanaka R, Farias E, Kadamb R, Lopez-Anton M, Heine CC, Modasia B, Aguirre-Ghiso JA, Aplin AE, Sato T, Benovic JL. IGF1R inhibition enhances the therapeutic effects of Gq/11 inhibition in metastatic uveal melanoma progression. Molecular Cancer Therapeutics. PMID 36223548 DOI: 10.1158/1535-7163.MCT-22-0147 |
0.379 |
|
| 2022 |
Vernon M, Wilski NA, Kotas D, Cai W, Pomante D, Tiago M, Alnemri ES, Aplin AE. Raptinal induces Gasdermin E-dependent pyroptosis in naive and therapy-resistant melanoma. Molecular Cancer Research : McR. PMID 36044013 DOI: 10.1158/1541-7786.MCR-22-0040 |
0.306 |
|
| 2022 |
Cai W, Nguyen MQ, Wilski NA, Purwin TJ, Vernon M, Tiago M, Aplin AE. A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma. Cancer Research. PMID 35657206 DOI: 10.1158/0008-5472.CAN-21-3217 |
0.318 |
|
| 2022 |
Caksa S, Baqai U, Aplin AE. The future of targeted kinase inhibitors in melanoma. Pharmacology & Therapeutics. 239: 108200. PMID 35513054 DOI: 10.1016/j.pharmthera.2022.108200 |
0.356 |
|
| 2022 |
Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, Harbour JW, Aplin AE. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. Molecular Cancer Research : McR. PMID 35426938 DOI: 10.1158/1541-7786.MCR-21-0657 |
0.386 |
|
| 2022 |
Capparelli C, Purwin TJ, Glasheen M, Caksa S, Tiago M, Wilski N, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, ... ... Aplin AE, et al. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature Communications. 13: 1381. PMID 35296667 DOI: 10.1038/s41467-022-28801-y |
0.433 |
|
| 2022 |
Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, Harbour JW, Aplin AE. Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma. Oncogene. 41: 1129-1139. PMID 35046531 DOI: 10.1038/s41388-021-02154-0 |
0.408 |
|
| 2021 |
Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, J William H, Aplin AE. The AMP-Dependent Kinase Pathway is Upregulated in BAP1 Mutant Uveal Melanoma. Pigment Cell & Melanoma Research. PMID 34347929 DOI: 10.1111/pcmr.13007 |
0.473 |
|
| 2021 |
Ohara M, Saito K, Kageyama K, Terai M, Cheng H, Aplin AE, Sato T. Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. Cancers. 13. PMID 33806615 DOI: 10.3390/cancers13051104 |
0.379 |
|
| 2021 |
Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Lubrano S, Gomes FG, Arang N, Tiago M, Coma S, Wu X, Ford K, Day CP, Merlino G, Mali P, Pachter JA, ... ... Aplin AE, et al. Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for -Driven Uveal Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33568347 DOI: 10.1158/1078-0432.CCR-20-3363 |
0.34 |
|
| 2020 |
Vido MJ, Rock J, Aplin AE. Role of serine 365 in BRAF V600E sensitivity to RAF inhibition. Pigment Cell & Melanoma Research. PMID 33000894 DOI: 10.1111/pcmr.12932 |
0.332 |
|
| 2020 |
Teh JL, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T cells contributes to anti-tumor effects of CDK4/6 inhibitors plus MEK inhibitors. Cancer Immunology Research. PMID 32661093 DOI: 10.1158/2326-6066.Cir-19-0743 |
0.32 |
|
| 2020 |
Teh JL, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso JA, Aplin AE. Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma. Molecular Cancer Therapeutics. PMID 32430489 DOI: 10.1158/1535-7163.MCT-19-1016 |
0.458 |
|
| 2020 |
Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. The Journal of Investigative Dermatology. PMID 32389536 DOI: 10.1016/J.Jid.2020.02.047 |
0.407 |
|
| 2020 |
Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Reports. 30: 510-524.e6. PMID 31940493 DOI: 10.1016/J.Celrep.2019.12.036 |
0.388 |
|
| 2020 |
Tiago M, Capparelli C, Erkes DA, Purwin TJ, Heilman SA, Berger AC, Davies MA, Aplin AE. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. British Journal of Cancer. PMID 31932756 DOI: 10.1038/S41416-019-0724-Y |
0.349 |
|
| 2019 |
Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discovery. PMID 31796433 DOI: 10.1158/2159-8290.Cd-19-0672 |
0.362 |
|
| 2019 |
Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell & Melanoma Research. PMID 31758842 DOI: 10.1111/Pcmr.12849 |
0.345 |
|
| 2019 |
Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. Molecular Cancer Therapeutics. PMID 31270153 DOI: 10.1158/1535-7163.Mct-18-1056 |
0.441 |
|
| 2019 |
Petit V, Raymond J, Alberti C, Pouteaux M, Gallagher SJ, Nguyen MQ, Aplin AE, Delmas V, Larue L. C57BL/6 congenic mouse NRAS melanoma cell lines are highly sensitive to the combination of MEK and AKT inhibitors in vitro and in vivo. Pigment Cell & Melanoma Research. PMID 31251472 DOI: 10.1111/Pcmr.12807 |
0.324 |
|
| 2019 |
Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death & Disease. 10: 281. PMID 30911007 DOI: 10.1038/S41419-019-1515-3 |
0.399 |
|
| 2019 |
Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Inhibition of NF-κB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma. Cancer Research. PMID 30885979 DOI: 10.1158/0008-5472.Can-18-3177 |
0.373 |
|
| 2019 |
Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. Embo Molecular Medicine. PMID 30610113 DOI: 10.15252/emmm.201809081 |
0.375 |
|
| 2018 |
Lapadula D, Farias E, Randolph CE, Purwin T, McGrath D, Charpentier T, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner P, Aplin AE, Aguirre-Ghiso J, et al. Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma. Molecular Cancer Research : McR. PMID 30567972 DOI: 10.1158/1541-7786.Mcr-18-0574 |
0.469 |
|
| 2018 |
Vido MJ, Le K, Hartsough EJ, Aplin AE. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Reports. 25: 1501-1510.e3. PMID 30404005 DOI: 10.1016/J.Celrep.2018.10.049 |
0.339 |
|
| 2018 |
Teh JL, Aplin AE. Arrested developments: CDK4/6 inhibitor resistance and alterations in the tumor immune microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30287548 DOI: 10.1158/1078-0432.CCR-18-1967 |
0.358 |
|
| 2018 |
Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma. Cancer Research. PMID 30115691 DOI: 10.1158/0008-5472.Can-18-1001 |
0.4 |
|
| 2018 |
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, ... ... Aplin AE, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/Emmm.201708446 |
0.344 |
|
| 2018 |
Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FC, Li J, Teh JL, Aplin AE, Chen M, Zhang J, Lazar AJ, et al. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discovery. PMID 29496665 DOI: 10.1158/2159-8290.Cd-17-0745 |
0.3 |
|
| 2018 |
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. Cancer Discovery. PMID 29496664 DOI: 10.1158/2159-8290.Cd-17-0699 |
0.351 |
|
| 2018 |
Brożyna AA, Aplin A, Cohen C, Carlson G, Page AJ, Murphy M, Slominski AT, Carlson JA. CKS1 expression in melanocytic nevi and melanoma. Oncotarget. 9: 4173-4187. PMID 29423113 DOI: 10.18632/Oncotarget.23648 |
0.4 |
|
| 2018 |
Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, ... ... Aplin AE, et al. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nature Communications. 9: 28. PMID 29295999 DOI: 10.1038/s41467-017-02354-x |
0.489 |
|
| 2018 |
Chua V, Purwin T, Liao C, Aplin A. Abstract 5852: FGF2 confers resistance to novel BET inhibitors in metastatic uveal melanoma Cancer Research. 78: 5852-5852. DOI: 10.1158/1538-7445.Am2018-5852 |
0.534 |
|
| 2017 |
Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and resistance to paradox breaking BRAF inhibitor in melanomas in vivo and ex vivo. Molecular Cancer Therapeutics. PMID 29133617 DOI: 10.1158/1535-7163.Mct-17-0705 |
0.44 |
|
| 2017 |
Sample A, Zhao B, Wu C, Qian S, Shi X, Aplin A, He YY. The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochemistry and Photobiology. PMID 28715145 DOI: 10.1111/Php.12809 |
0.417 |
|
| 2017 |
Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF-cMET signaling with MEK inhibitors in metastatic uveal melanoma. Molecular Cancer Therapeutics. PMID 28138035 DOI: 10.1158/1535-7163.Mct-16-0552 |
0.474 |
|
| 2017 |
Teh J, Nikbakht N, Purwin T, Chervoneva I, Patel P, Davies M, Aplin A. Abstract 2350: In vivo E2F reporting on efficacious dosing schedules of MEK plus CDK4/6 inhibition in melanoma Cancer Research. 77: 2350-2350. DOI: 10.1158/1538-7445.Am2017-2350 |
0.318 |
|
| 2016 |
Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma. Cancer Research. PMID 27488531 DOI: 10.1158/0008-5472.Can-15-3384 |
0.396 |
|
| 2016 |
Vu HL, Aplin AE. Targeting mutant NRAS signaling pathways in melanoma. Pharmacological Research. 107: 111-6. PMID 26987942 DOI: 10.1016/j.phrs.2016.03.007 |
0.343 |
|
| 2016 |
Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. The Journal of Investigative Dermatology. 136: 453-463. PMID 26967478 DOI: 10.1016/J.Jid.2015.11.012 |
0.489 |
|
| 2016 |
Teh JL, Purwin T, Greenawalt EJ, Chervoneva I, Goldberg A, Davies ME, Aplin A. Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma Cancer Research. 76: 5199-5199. DOI: 10.1158/1538-7445.Am2016-5199 |
0.488 |
|
| 2016 |
Cheng H, Kageyama K, Purwin T, Liao C, Terai M, Sato T, Aplin A. Abstract 4664: Co-targeting HGF-cMET signaling with MEK inhibitors in metastatic uveal melanoma Cancer Research. 76: 4664-4664. DOI: 10.1158/1538-7445.Am2016-4664 |
0.444 |
|
| 2015 |
Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, et al. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. The American Journal of Pathology. 185: 2505-22. PMID 26362718 DOI: 10.1016/J.Ajpath.2015.04.026 |
0.421 |
|
| 2015 |
Capparelli C, Rosenbaum S, Berger AC, Aplin AE. Fibroblast-Derived Neuregulin-1 Promotes Compensatory ErbB3 Signaling in Mutant BRAF Melanoma. The Journal of Biological Chemistry. PMID 26269601 DOI: 10.1074/Jbc.M115.657270 |
0.479 |
|
| 2015 |
Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research. 75: 3554-67. PMID 26206558 DOI: 10.1158/0008-5472.Can-14-2959 |
0.391 |
|
| 2015 |
Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. The Journal of Biological Chemistry. 290: 21901-14. PMID 26205821 DOI: 10.1074/Jbc.M115.670976 |
0.347 |
|
| 2015 |
Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Research. 75: 2737-48. PMID 25952648 DOI: 10.1158/0008-5472.Can-15-0370 |
0.34 |
|
| 2015 |
Shao Y, Le K, Cheng H, Aplin AE. NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma. The Journal of Investigative Dermatology. 135: 1839-48. PMID 25751672 DOI: 10.1038/Jid.2015.91 |
0.378 |
|
| 2015 |
Sanchez I, Aplin A. Abstract B28: In vivo ERK1/2 pathway reporting during acquired resistance to combined RAF/MEK inhibition Cancer Research. 75: 2686-2686. DOI: 10.1158/1538-7445.Mel2014-B28 |
0.517 |
|
| 2015 |
Teh JL, Aplin A. Abstract 3096: CDK4/6 as a therapeutic target in malignant melanoma Cancer Research. 75: 3096-3096. DOI: 10.1158/1538-7445.Am2015-3096 |
0.543 |
|
| 2015 |
Cheng H, Terai M, Sato T, Aplin A. Abstract 2685: Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma Cancer Research. 75: 2685-2685. DOI: 10.1158/1538-7445.Am2015-2685 |
0.502 |
|
| 2014 |
Zhao B, Shah P, Budanov AV, Qiang L, Ming M, Aplin A, Sims DM, He YY. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells. The Journal of Biological Chemistry. 289: 35806-14. PMID 25378405 DOI: 10.1074/Jbc.M114.595397 |
0.479 |
|
| 2014 |
Weiss MB, Abel EV, Dadpey N, Aplin AE. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma. Molecular Cancer Research : McR. 12: 1314-23. PMID 25061102 DOI: 10.1158/1541-7786.MCR-14-0170 |
0.376 |
|
| 2014 |
Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Research. 74: 4122-32. PMID 25035390 DOI: 10.1158/0008-5472.Can-14-0464 |
0.426 |
|
| 2014 |
Vu HL, Aplin AE. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma. Molecular Cancer Research : McR. 12: 1509-19. PMID 24962318 DOI: 10.1158/1541-7786.MCR-14-0204 |
0.492 |
|
| 2014 |
Kugel CH, Aplin AE. Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell & Melanoma Research. 27: 1032-8. PMID 24828387 DOI: 10.1111/pcmr.12264 |
0.329 |
|
| 2014 |
Hartsough EJ, Basile KJ, Aplin AE. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Molecular Cancer Research : McR. 12: 795-802. PMID 24520098 DOI: 10.1158/1541-7786.Mcr-13-0581 |
0.452 |
|
| 2014 |
Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell & Melanoma Research. 27: 479-84. PMID 24422853 DOI: 10.1111/Pcmr.12218 |
0.479 |
|
| 2014 |
Sanchez IM, Aplin AE. Hippo: hungry, hungry for melanoma invasion. The Journal of Investigative Dermatology. 134: 14-6. PMID 24352079 DOI: 10.1038/jid.2013.372 |
0.34 |
|
| 2014 |
Hartsough E, Shao Y, Aplin AE. Resistance to RAF inhibitors revisited. The Journal of Investigative Dermatology. 134: 319-25. PMID 24108405 DOI: 10.1038/Jid.2013.358 |
0.353 |
|
| 2013 |
Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Research. 73: 7101-10. PMID 24121492 DOI: 10.1158/0008-5472.Can-13-1628 |
0.367 |
|
| 2013 |
Hartsough EJ, Aplin AE. A STATement on vemurafenib-resistant melanoma. The Journal of Investigative Dermatology. 133: 1928-9. PMID 23856932 DOI: 10.1038/Jid.2013.136 |
0.301 |
|
| 2013 |
Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. The Journal of Clinical Investigation. 123: 2155-68. PMID 23543055 DOI: 10.1172/Jci65780 |
0.417 |
|
| 2013 |
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell & Melanoma Research. 26: E8-E14. PMID 23531109 DOI: 10.1111/Pcmr.12099 |
0.302 |
|
| 2013 |
Le K, Blomain ES, Rodeck U, Aplin AE. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell & Melanoma Research. 26: 509-17. PMID 23490205 DOI: 10.1111/pcmr.12092 |
0.466 |
|
| 2013 |
Capparelli C, Gaborit N, Yarden Y, Aplin A. Abstract C44: Targeting neuregulin1-ErbB3 signaling in wild-type BRAF/NRAS melanoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C44 |
0.566 |
|
| 2012 |
Basile KJ, Aplin AE. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. American Journal of Cancer Research. 2: 726-35. PMID 23226618 |
0.53 |
|
| 2012 |
Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Research. 72: 6382-92. PMID 23222305 DOI: 10.1158/0008-5472.Can-12-1033 |
0.448 |
|
| 2012 |
Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. The Journal of Biological Chemistry. 287: 41797-807. PMID 23076151 DOI: 10.1074/jbc.M112.390906 |
0.495 |
|
| 2012 |
Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death and Differentiation. 19: 2029-39. PMID 22858545 DOI: 10.1038/cdd.2012.94 |
0.588 |
|
| 2012 |
Shao Y, Aplin AE. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death & Disease. 3: e253. PMID 22258404 DOI: 10.1038/cddis.2011.137 |
0.555 |
|
| 2012 |
Basile KJ, Abel EV, Aplin AE. Abstract B8: FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib Clinical Cancer Research. 18: B8-B8. DOI: 10.1158/1078-0432.MECHRES-B8 |
0.306 |
|
| 2011 |
Aplin AE. Axl of evil? The Journal of Investigative Dermatology. 131: 2343-5. PMID 22071539 DOI: 10.1038/jid.2011.308 |
0.396 |
|
| 2011 |
Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene. 31: 2471-9. PMID 21996740 DOI: 10.1038/onc.2011.424 |
0.573 |
|
| 2011 |
Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. The Journal of Investigative Dermatology. 131: 1817-20. PMID 21593776 DOI: 10.1038/jid.2011.147 |
0.309 |
|
| 2011 |
Katiyar P, Aplin AE. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells. Molecular Cancer Research : McR. 9: 545-52. PMID 21478267 DOI: 10.1158/1541-7786.MCR-10-0454 |
0.546 |
|
| 2011 |
Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene. 30: 366-71. PMID 20818433 DOI: 10.1038/onc.2010.408 |
0.484 |
|
| 2010 |
Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP, Capozza F. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Research. 70: 7489-99. PMID 20709760 DOI: 10.1158/0008-5472.Can-10-0900 |
0.442 |
|
| 2010 |
Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Research. 70: 6670-81. PMID 20647317 DOI: 10.1158/0008-5472.CAN-09-4471 |
0.585 |
|
| 2010 |
Kaplan FM, Mastrangelo MJ, Aplin AE. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. The Journal of Investigative Dermatology. 130: 2669-71. PMID 20574441 DOI: 10.1038/jid.2010.177 |
0.345 |
|
| 2010 |
Abel EV, Aplin AE. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Research. 70: 2891-900. PMID 20332228 DOI: 10.1158/0008-5472.CAN-09-3139 |
0.586 |
|
| 2010 |
Hu R, Aplin AE. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. Pigment Cell & Melanoma Research. 23: 201-9. PMID 20067552 DOI: 10.1111/j.1755-148X.2010.00668.x |
0.551 |
|
| 2009 |
Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. Mcl-1 is required for melanoma cell resistance to anoikis. Molecular Cancer Research : McR. 7: 549-56. PMID 19372583 DOI: 10.1158/1541-7786.Mcr-08-0358 |
0.732 |
|
| 2009 |
Klein RM, Aplin AE. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Research. 69: 2224-33. PMID 19244113 DOI: 10.1158/0008-5472.CAN-08-3201 |
0.502 |
|
| 2008 |
Hu R, Aplin AE. Skp2 regulates G2/M progression in a p53-dependent manner. Molecular Biology of the Cell. 19: 4602-10. PMID 18716061 DOI: 10.1091/mbc.E07-11-1137 |
0.444 |
|
| 2008 |
Boisvert-Adamo K, Aplin AE. Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene. 27: 3301-12. PMID 18246127 DOI: 10.1038/sj.onc.1211003 |
0.729 |
|
| 2008 |
Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Molecular Biology of the Cell. 19: 498-508. PMID 18045987 DOI: 10.1091/mbc.E07-09-0895 |
0.508 |
|
| 2007 |
Carlson JA, Linette GP, Aplin A, Ng B, Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatologic Clinics. 25: 541-57, viii-ix. PMID 17903613 DOI: 10.1016/J.Det.2007.06.005 |
0.373 |
|
| 2006 |
Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene. 26: 1056-66. PMID 16924241 DOI: 10.1038/sj.onc.1209861 |
0.509 |
|
| 2006 |
Spofford LS, Abel EV, Boisvert-Adamo K, Aplin AE. Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression. The Journal of Biological Chemistry. 281: 25644-51. PMID 16815849 DOI: 10.1074/Jbc.M600197200 |
0.696 |
|
| 2006 |
Boisvert-Adamo K, Aplin AE. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene. 25: 4848-56. PMID 16547495 DOI: 10.1038/sj.onc.1209493 |
0.731 |
|
| 2005 |
Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene. 24: 3459-71. PMID 15735667 DOI: 10.1038/Sj.Onc.1208544 |
0.509 |
|
| 2004 |
Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A. Integrin regulation of cell signalling and motility. Biochemical Society Transactions. 32: 443-6. PMID 15157156 DOI: 10.1042/Bst0320443 |
0.54 |
|
| 2003 |
Conner SR, Scott G, Aplin AE. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. The Journal of Biological Chemistry. 278: 34548-54. PMID 12821662 DOI: 10.1074/Jbc.M305797200 |
0.583 |
|
| 2003 |
Aplin AE. Cell adhesion molecule regulation of nucleocytoplasmic trafficking. Febs Letters. 534: 11-4. PMID 12527355 |
0.353 |
|
| 2002 |
Aplin AE, Hogan BP, Tomeu J, Juliano RL. Cell adhesion differentially regulates the nucleocytoplasmic distribution of active MAP kinases. Journal of Cell Science. 115: 2781-90. PMID 12077368 |
0.437 |
|
| 2002 |
Howe AK, Aplin AE, Juliano RL. Anchorage-dependent ERK signaling--mechanisms and consequences. Current Opinion in Genetics & Development. 12: 30-5. PMID 11790551 DOI: 10.1016/S0959-437X(01)00260-X |
0.459 |
|
| 2001 |
Aplin AE, Juliano RL. Regulation of nucleocytoplasmic trafficking by cell adhesion receptors and the cytoskeleton. The Journal of Cell Biology. 155: 187-91. PMID 11604417 DOI: 10.1083/Jcb.200107116 |
0.315 |
|
| 2001 |
Juliano RL, Aplin AE, Howe AK, Short S, Lee JW, Alahari S. Integrin regulation of receptor tyrosine kinase and G protein-coupled receptor signaling to mitogen-activated protein kinases. Methods in Enzymology. 333: 151-63. PMID 11400332 DOI: 10.1016/S0076-6879(01)33053-7 |
0.405 |
|
| 2001 |
Aplin AE, Stewart SA, Assoian RK, Juliano RL. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1 Journal of Cell Biology. 153: 273-281. PMID 11309409 DOI: 10.1083/Jcb.153.2.273 |
0.445 |
|
| 2000 |
Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Current Opinion in Cell Biology. 11: 737-44. PMID 10600702 DOI: 10.1016/S0955-0674(99)00045-9 |
0.35 |
|
| 1999 |
Aplin AE, Short SM, Juliano RL. Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains. The Journal of Biological Chemistry. 274: 31223-8. PMID 10531317 DOI: 10.1074/Jbc.274.44.31223 |
0.355 |
|
| 1998 |
Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Current Opinion in Cell Biology. 10: 220-31. PMID 9561846 DOI: 10.1016/S0955-0674(98)80144-0 |
0.362 |
|
| 1997 |
Lin TH, Aplin AE, Shen Y, Chen Q, Schaller M, Romer L, Aukhil I, Juliano RL. Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. The Journal of Cell Biology. 136: 1385-95. PMID 9087451 DOI: 10.1083/Jcb.136.6.1385 |
0.364 |
|
| Show low-probability matches. |